MVT 2163

Drug Profile

MVT 2163

Alternative Names: 89Zr-DFO-HuMab-5B1; 89Zr-HuMab 5B1; anti-sialyl Lewisa imaging agent - MabVax; MVT-2163; radiolabeled HuMab 5B1 antibody; radiolabelled 5B1 antibody; radiolabelled 5B1 diabody; radiolabelled anti-CA 19.9 antibody

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class Drug conjugates; Imaging agents; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Diagnostic imaging enhancers; Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer
  • Preclinical Bladder cancer; Colorectal cancer; Small cell lung cancer

Most Recent Events

  • 22 Aug 2017 MabVax completes the phase I trial in Pancreatic cancer (Diagnosis, Late-stage disease, Metastatic disease) in USA, before August 2017
  • 14 Jun 2017 Pharmacokinetics and safety data from a phase I trial in Pancreatic cancer (Diagnosis) released by MabVax
  • 07 Nov 2016 MabVax Therapeutics has patent protection for MVT 2163 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top